But as I have previously stated, the company HAVE with numerous 8/10 k's said that they know no reason for investors not to invest.(paraphrasing) If they were hiding anything at all - as you say - if this trial fails this will open the floodgates to many lawsuits which is why it simply did not happen IMO
And it is that interim, the one expected in the summer of 2015 (coincident with the FDA clinical hold) where I am suggesting futility was observed on PFS.
Avii, how did the FDA find out about this futility result on the 2nd IA if the co never released it and kept it secret according to you? So why the hold again? I am not familiar with the broad history of futility recommendations in the past, but I strongly suspect that they did not always get a hold response from the FDA if the co decided to continue with the trial.